AOD-9604
AOD-9604 is a 16-amino-acid fragment lifted from the tail end of human growth hormone, engineered in the 1990s in the hope of capturing the hormone fat-burning effect without its growth-promoting and blood-sugar-raising side effects. Early animal work and a small 12-week human trial of 300 people looked promising, with the treated group losing about 2.6 kilograms versus 0.8 for placebo. But the pivotal, adequately powered follow-up trial of 536 adults over 24 weeks failed to beat placebo for weight loss, and its sponsor ended the drug development program in 2007. That negative result was disclosed only in a company announcement and, notably, was never published in a peer-reviewed journal, a gap that itself says something about how the evidence should be weighed. AOD-9604 is not approved anywhere and is sold today only as an unregulated research chemical, often marketed using its earlier, more encouraging results rather than the trial that actually decided its fate. Its story is a useful caution: a peptide with a plausible mechanism and early promise that a properly sized human trial did not confirm.
Key Takeaways
- • AOD-9604 is a synthetic 16-amino-acid peptide corresponding to a modified version of the C-terminal fragment (residues 176 to 191) of human growth hormone, the region identified in the 1990s by Frank Ng and colleagues at Monash University as responsible for growth hormone lipolytic (fat-mobilizing) activity, distinct from the region responsible for its growth-promoting and insulin-antagonistic (diabetogenic) effects.
- • Preclinical studies in obese mice (in vivo, rodent) found that chronic administration of AOD-9604 increased fat oxidation and reduced body weight without the significant rise in IGF-1 seen with full-length growth hormone, and a follow-up study in beta-3-adrenergic-receptor knockout mice found the lipolytic effect disappeared entirely in the knockout animals, establishing that AOD-9604 lipolytic action depends on an intact beta-3-adrenergic receptor (ADRB3) pathway rather than on growth-hormone-receptor signaling.
- • An early 12-week phase 2a human trial (randomized, placebo-controlled, n=300 obese adults, oral dosing) reported that the 1 milligram daily dose group lost a mean of 2.6 kilograms compared with 0.8 kilograms for placebo, alongside modest improvements in cholesterol and glucose tolerance measures, results that generated substantial commercial and media interest at the time.
- • The pivotal, larger, and longer confirmatory trial (a 24-week, placebo-controlled, adequately powered phase 2b study, n=536 obese adults, known as the OPTIONS study) failed to demonstrate a statistically significant weight-loss benefit over placebo, and its sponsor, Metabolic Pharmaceuticals, terminated AOD-9604 clinical development for obesity in 2007 as a direct consequence.
- • The negative pivotal phase 2b trial result was disclosed only through a company press release and, despite enrolling more than 500 participants in an adequately powered design, does not appear to have ever been published in a peer-reviewed journal, an important and specific evidence-quality gap distinct from the more common problem of simply having too little human data.
- • No controlled human trial completed since 2007 has re-evaluated AOD-9604 for obesity, body composition, cartilage or joint health, or any other outcome for which it is currently marketed; all human trial data specific to AOD-9604 dates to the mid-2000s phase 2a and phase 2b program described above.
- • AOD-9604 is not approved by the FDA, EMA, or any other regulatory authority for any indication, is not manufactured under pharmaceutical quality control, and is sold today exclusively through research-chemical vendors and compounding sources, frequently marketed using the encouraging phase 2a results while omitting or minimizing the negative pivotal phase 2b outcome that ended its formal drug development.
Basic Information
- Name
- AOD-9604
- Also Known As
- AOD-9604AOD9604hGH Fragment 176-191 (modified)Anti-Obesity Drug 9604Metabolic AOD9604
- Category
- Modified C-terminal fragment of human growth hormone; selective beta-3-adrenergic receptor pathway activator; research-only, discontinued drug candidate
- Bioavailability
- AOD-9604 has been studied in both oral and subcutaneous injectable forms across its development history, an unusual duality among the peptides in this queue, most of which are limited to injectable routes because of gastrointestinal degradation. The pivotal phase 2a and phase 2b human obesity trials used oral, once-daily dosing, indicating some degree of oral bioavailability was achieved in the formulation used, though the specific absolute oral bioavailability figure was not disclosed in the available public literature from that trial program. Current research-chemical vendors sell AOD-9604 predominantly as a subcutaneously injected, lyophilized powder requiring reconstitution with bacteriostatic water, a formulation and route that differs from the oral form used in its pivotal human trials, meaning pharmacokinetic data from the original oral trials may not directly apply to the injectable product now sold.
- Half-Life
- A specific, well-characterized human elimination half-life for AOD-9604 has not been established in the available public literature from its original phase 2 development program. As a small peptide fragment lacking any albumin-binding or protease-resistance modification comparable to those used in later-generation peptides such as CJC-1295 or semaglutide, AOD-9604 would be expected, based on its size and structure, to have a short plasma half-life on the order of minutes to a few hours if administered by injection, though this has not been directly measured and published for AOD-9604 specifically. The oral formulation used in its pivotal human trials implies some degree of formulation-dependent absorption and stability that has not been transparently characterized in the peer-reviewed literature.
Primary Mechanisms
Corresponds to a modified version of amino acids 176 to 191 at the carboxy terminus of human growth hormone, the specific domain identified as responsible for growth hormone lipolytic (fat-mobilizing) activity, separate from the domain responsible for its growth-promoting and diabetogenic effects
Activates lipolysis through upregulation and sensitization of beta-3-adrenergic receptors (ADRB3) on white and, to a lesser extent, brown adipocyte cell membranes, rather than through the growth-hormone-receptor (GHR) pathway used by full-length growth hormone
Does not meaningfully activate the growth hormone receptor and, consistent with this, has not been associated with the significant IGF-1 elevation characteristic of full-length growth hormone or growth hormone secretagogues in the available preclinical and human data
In beta-3-adrenergic-receptor knockout mice, the lipolytic and weight-reducing effect of AOD-9604 is completely abolished, direct genetic evidence that ADRB3 signaling is necessary for its mechanism of action rather than an incidental correlate
Proposed to increase fat oxidation preferentially, based on rodent data, though the specific tissue selectivity (visceral versus subcutaneous fat) has not been characterized with the same precision as more recent incretin-based or GHRH-based peptides in this queue
Quick Safety Summary
The pivotal human trial program tested oral AOD-9604 doses of 0 (placebo), 1, 5, 10, 20, and 30 milligrams daily in the earlier phase 2a trial (n=300, 12 weeks), with the 1 milligram dose producing the largest reported weight-loss effect; notably, higher doses in that trial did not show a clearly dose-dependent greater effect, an atypical dose-response pattern. The larger confirmatory phase 2b trial (n=536, 24 weeks) tested a range of doses within a similar range and found no statistically significant weight-loss benefit over placebo at any dose tested. No dose of AOD-9604 has been established as safe or effective in a confirmatory human trial, and current research-chemical vendor dosing recommendations for injectable AOD-9604 are not derived from either published human trial, both of which used oral dosing.
Active malignancy or history of cancer: because AOD-9604 is derived from human growth hormone and its full long-term safety profile in humans beyond a 24-week trial has not been established, individuals with active malignancy or a significant cancer history should be aware of the general theoretical caution applied to growth-hormone-derived compounds, even though AOD-9604 was specifically engineered to avoid growth-hormone-receptor-mediated proliferative signaling, Pregnancy and breastfeeding: no human safety data exist for AOD-9604 use during pregnancy or lactation, Reliance on AOD-9604 in place of an evaluated weight-management approach: because the pivotal, adequately powered human trial found no significant weight-loss benefit over placebo, using AOD-9604 as a primary weight-management strategy substitutes an unconfirmed intervention for approaches with a stronger evidence base, including FDA-approved incretin therapies covered elsewhere in this queue, Individuals seeking AOD-9604 based on marketing that cites only the early phase 2a results: because the larger, more methodologically reliable phase 2b trial found no benefit, decisions based only on the earlier positive signal reflect an incomplete and misleading reading of the total evidence, Use of unregulated, research-chemical-grade product: because AOD-9604 is sold exclusively through research-chemical vendors with no pharmaceutical quality-control oversight, actual peptide content, purity, and sterility have not been independently verified across vendors
Overview
AOD-9604 is a synthetic peptide corresponding to a modified version of amino acids 176 to 191 at the carboxy terminus of human growth hormone. In the 1990s, Frank Ng and colleagues at Monash University in Melbourne identified this C-terminal region as the specific domain responsible for growth hormone lipolytic, or fat-mobilizing, activity, distinct from the domains responsible for its growth-promoting and diabetogenic (insulin-antagonistic) effects. The therapeutic rationale for AOD-9604 was to isolate and exploit this fat-burning domain in a small, synthesizable peptide while leaving behind the side effects associated with the rest of the growth hormone molecule. The compound was developed and taken into human trials by the Australian company Metabolic Pharmaceuticals during the 2000s, generating substantial commercial and media interest after an early, smaller human trial reported encouraging weight-loss results.
The core mechanism of AOD-9604, established through preclinical rodent studies, is activation of lipolysis via upregulation and sensitization of beta-3-adrenergic receptors (ADRB3) on adipocyte cell membranes, rather than through the growth-hormone-receptor (GHR) pathway used by full-length growth hormone. A pivotal 2001 study in beta-3-adrenergic-receptor knockout mice found that the lipolytic and weight-reducing effect of AOD-9604, clearly present in wild-type mice, was completely absent in the knockout animals, direct genetic evidence that this receptor pathway is mechanistically necessary rather than merely correlated. Consistent with its design goal of excluding growth-hormone-receptor activity, AOD-9604 has not been associated with the significant IGF-1 elevation characteristic of full-length growth hormone or of growth hormone secretagogues such as sermorelin or CJC-1295 covered elsewhere in this queue, a mechanistically favorable distinction from that class even though its overall clinical efficacy question was ultimately settled differently.
The AOD-9604 human evidence base tells a specific and instructive story about the difference between an early positive signal and a confirmatory result. An initial phase 2a trial (randomized, placebo-controlled, n=300 obese adults, 12 weeks, oral dosing) reported that the 1 milligram daily dose group lost a mean of 2.6 kilograms compared with 0.8 kilograms for placebo, along with modest improvements in cholesterol and glucose tolerance measures. This result generated considerable optimism and investment, but the larger, longer, and purpose-built confirmatory trial that followed, a 24-week, adequately powered, placebo-controlled phase 2b study enrolling 536 obese adults, failed to demonstrate a statistically significant weight-loss benefit over placebo. Metabolic Pharmaceuticals terminated the compound clinical development for obesity in 2007 as a direct result. Notably, and importantly for evaluating claims made about AOD-9604 today, this negative pivotal trial result was disclosed only through a company press release and does not appear to have ever been published in a peer-reviewed journal, meaning the specific trial that determined the compound clinical fate cannot be independently scrutinized in the way a published trial can.
From a regulatory and practical standpoint, AOD-9604 is not approved by the FDA, the EMA, or any other regulatory authority for any indication, and no controlled human trial has re-evaluated it for obesity or any other outcome since its 2007 development termination. It is sold today exclusively through research-chemical vendors and some compounding sources, in both oral and injectable forms, none manufactured under pharmaceutical quality-control standards. Marketing for AOD-9604 frequently emphasizes the encouraging early phase 2a trial results while omitting or minimizing the negative, larger, and more methodologically reliable phase 2b outcome that actually ended its formal drug development, a pattern of selective evidence presentation that anyone considering the compound should be aware of. As a fragment derived from human growth hormone, AOD-9604 is also included within the growth hormone and growth hormone fragment class prohibited by the World Anti-Doping Agency, relevant to any athlete considering its use.
Core Health Impacts
- • Fat Oxidation and Weight Loss in Obese Mice (Animal, In Vivo): A 2001 study in obese mice found that chronic administration of AOD-9604 increased fat oxidation and reduced body weight and body fat over 14 days, an effect comparable in direction to full-length human growth hormone but without the corresponding significant rise in IGF-1, the growth-promoting hormone associated with the diabetogenic and tissue-growth side effects of growth hormone itself. This is a rodent finding and has not been replicated with the same mechanistic detail in a human trial.
- • Dependence on Beta-3-Adrenergic Receptor Signaling (Animal, In Vivo): A companion 2001 study conducted in beta-3-adrenergic-receptor (ADRB3) knockout mice found that the lipolytic and weight-reducing effect of AOD-9604 seen in wild-type mice was completely absent in the knockout animals, establishing that the peptide fat-mobilizing action depends on an intact ADRB3 pathway rather than on the growth-hormone-receptor pathway used by full-length growth hormone. This mechanistic finding is well-characterized in mice but has not been directly confirmed with receptor-blockade experiments in humans.
- • Modest Weight Loss in an Early 12-Week Human Trial (Human, Phase 2a): An early phase 2a trial (randomized, placebo-controlled, n=300 obese adults) found that oral AOD-9604 at 1 milligram daily produced a mean weight loss of 2.6 kilograms over 12 weeks compared with 0.8 kilograms for placebo, more than triple the placebo effect, alongside modest improvements in cholesterol profile and a reduction in the proportion of participants with impaired glucose tolerance. This trial generated substantial early optimism but was smaller and shorter than the confirmatory trial that followed.
- • Failure to Confirm Weight-Loss Benefit in the Pivotal Trial (Human, Phase 2b): The larger, longer, and adequately powered confirmatory trial (24 weeks, n=536 obese adults, placebo-controlled) failed to demonstrate a statistically significant weight-loss benefit of AOD-9604 over placebo across the doses tested. This negative result, rather than the earlier positive phase 2a signal, is the more methodologically reliable finding given its larger sample size, longer duration, and purpose-built confirmatory design, and it directly led to termination of the drug clinical development program in 2007.
- • Absence of Peer-Reviewed Publication of the Pivotal Negative Trial (Evidence-Quality Finding): Despite enrolling 536 participants in an adequately powered, placebo-controlled design, the pivotal phase 2b trial results were disclosed only through a company press release and do not appear to have been published in a peer-reviewed journal. This is a distinct and important evidence-quality concern: negative trials that go unpublished are a well-documented source of publication bias in the pharmaceutical literature generally, and in AOD-9604 case, it means the specific trial that determined the compound clinical fate cannot be independently scrutinized through standard peer review.
- • No Significant Rise in IGF-1 or Growth-Promoting Activity (Animal and Limited Human Data): Across the available preclinical and early human data, AOD-9604 has not been associated with the significant IGF-1 elevation or growth-promoting activity seen with full-length growth hormone, consistent with its design rationale of isolating the lipolytic domain from the growth-hormone-receptor-binding domain. This is considered a favorable safety distinction from full-length growth hormone or growth hormone secretagogues, though it has not been confirmed with dedicated long-term human IGF-1 monitoring specific to AOD-9604.
- • Claimed Joint and Cartilage Repair Effects (Unsupported by Controlled Human Data): Beyond weight loss, AOD-9604 is currently marketed by research-chemical vendors for joint and cartilage health, extrapolating from growth hormone general role in connective tissue metabolism. No controlled human trial has tested AOD-9604 for joint or cartilage outcomes; this use has no basis in the mid-2000s phase 2a or phase 2b trial program, both of which studied obesity and weight loss exclusively.
Gene Interactions
Key Gene Targets
GH1
AOD-9604 is a synthetic fragment corresponding to amino acids 176 to 191 of the growth hormone protein encoded by GH1, isolated specifically because this C-terminal region carries the hormone lipolytic activity separate from its growth-promoting domain; unlike growth hormone secretagogues elsewhere in this queue, AOD-9604 does not stimulate endogenous GH1 expression or secretion, it is itself a direct structural fragment of the GH1 gene product.
Also mentioned in
Safety & Dosing
Contraindications
Active malignancy or history of cancer: because AOD-9604 is derived from human growth hormone and its full long-term safety profile in humans beyond a 24-week trial has not been established, individuals with active malignancy or a significant cancer history should be aware of the general theoretical caution applied to growth-hormone-derived compounds, even though AOD-9604 was specifically engineered to avoid growth-hormone-receptor-mediated proliferative signaling
Pregnancy and breastfeeding: no human safety data exist for AOD-9604 use during pregnancy or lactation
Reliance on AOD-9604 in place of an evaluated weight-management approach: because the pivotal, adequately powered human trial found no significant weight-loss benefit over placebo, using AOD-9604 as a primary weight-management strategy substitutes an unconfirmed intervention for approaches with a stronger evidence base, including FDA-approved incretin therapies covered elsewhere in this queue
Individuals seeking AOD-9604 based on marketing that cites only the early phase 2a results: because the larger, more methodologically reliable phase 2b trial found no benefit, decisions based only on the earlier positive signal reflect an incomplete and misleading reading of the total evidence
Use of unregulated, research-chemical-grade product: because AOD-9604 is sold exclusively through research-chemical vendors with no pharmaceutical quality-control oversight, actual peptide content, purity, and sterility have not been independently verified across vendors
Drug Interactions
Beta-blockers and other adrenergic-receptor-modulating medications: because AOD-9604 proposed mechanism depends on beta-3-adrenergic receptor activation, concurrent use of medications that broadly block adrenergic receptor signaling could theoretically blunt its intended lipolytic effect, though this has not been formally studied
Other growth-hormone-derived peptides or growth hormone secretagogues (sermorelin, CJC-1295, ipamorelin): co-administration has no established pharmacological rationale specific to AOD-9604 and has not been studied
Thyroid hormone replacement: adrenergic and thyroid signaling interact in normal lipid and energy metabolism, a general physiological consideration rather than an AOD-9604-specific documented interaction
Stimulant medications or supplements acting on adrenergic pathways (for example, ephedrine-containing products): concurrent use with a beta-3-adrenergic-pathway-dependent peptide has a plausible but formally untested rationale for additive adrenergic stimulation and associated cardiovascular effects
Common Side Effects
In the published phase 2a trial, AOD-9604 was generally reported as well tolerated at the doses tested, though detailed adverse-event tabulation from that trial is not extensively available in the public literature
Injection-site reactions (redness, itching, or discomfort) have been reported anecdotally with the injectable research-chemical form now sold, though this route was not the one used in either published human trial, both of which were oral
Because the pivotal phase 2b trial results were never published in a peer-reviewed journal, a detailed, independently reviewable adverse-event profile from the larger, longer confirmatory trial is not available in the public scientific literature
Long-term safety data beyond 24 weeks have not been generated for AOD-9604 in any published human trial
Studied Doses
The pivotal human trial program tested oral AOD-9604 doses of 0 (placebo), 1, 5, 10, 20, and 30 milligrams daily in the earlier phase 2a trial (n=300, 12 weeks), with the 1 milligram dose producing the largest reported weight-loss effect; notably, higher doses in that trial did not show a clearly dose-dependent greater effect, an atypical dose-response pattern. The larger confirmatory phase 2b trial (n=536, 24 weeks) tested a range of doses within a similar range and found no statistically significant weight-loss benefit over placebo at any dose tested. No dose of AOD-9604 has been established as safe or effective in a confirmatory human trial, and current research-chemical vendor dosing recommendations for injectable AOD-9604 are not derived from either published human trial, both of which used oral dosing.
Mechanism of Action
Isolation of the Lipolytic Domain from Full-Length Growth Hormone
Human growth hormone is a 191-amino-acid protein with functionally distinct domains: one region binds and activates the growth hormone receptor (GHR) to produce its growth-promoting and diabetogenic (insulin-antagonizing) effects, while a separate carboxy-terminal region, identified by Frank Ng and colleagues at Monash University in the 1990s, is responsible for its lipolytic, or fat-mobilizing, activity. AOD-9604 is a synthetic peptide corresponding to a modified version of this carboxy-terminal fragment, amino acids 176 to 191, engineered with the specific therapeutic rationale of capturing growth hormone fat-burning effect in a molecule small enough to synthesize cheaply while avoiding the GHR-mediated growth-promoting and blood-sugar-raising effects associated with the rest of the hormone.
Beta-3-Adrenergic Receptor-Dependent Lipolysis
Rather than acting through GHR, AOD-9604 activates lipolysis through upregulation and sensitization of beta-3-adrenergic receptors (ADRB3) on adipocyte cell membranes. A 2001 study in obese mice found that chronic AOD-9604 administration increased fat oxidation and reduced body weight and fat mass, comparable in direction to full-length growth hormone but without the corresponding IGF-1 rise. A companion study using beta-3-adrenergic-receptor knockout mice provided direct genetic confirmation of this mechanism: the lipolytic and weight-reducing effect present in wild-type mice was completely absent in animals lacking a functional ADRB3 gene, establishing that this receptor pathway is mechanistically necessary rather than an incidental correlate of AOD-9604 action.
Absence of Growth-Hormone-Receptor Activity and IGF-1 Elevation
Consistent with its design goal, AOD-9604 has not been associated with the significant IGF-1 elevation characteristic of full-length growth hormone or of growth hormone secretagogues such as sermorelin, CJC-1295, or tesamorelin, all covered elsewhere in this queue and all of which act by stimulating the pituitary to release endogenous growth hormone through the GHRH receptor. This distinction is mechanistically important: AOD-9604 is not a growth hormone secretagogue and does not raise growth hormone or IGF-1 levels through pituitary stimulation, it is instead a direct structural fragment of the growth hormone molecule itself, engineered to retain only the adrenergic-receptor-mediated lipolytic activity.
Clinical Evidence
Early Positive Signal (Phase 2a Trial)
An early phase 2a human trial, randomized and placebo-controlled, enrolled 300 obese adults and tested oral AOD-9604 across a dose range of 1 to 30 milligrams daily over 12 weeks. The 1 milligram dose group lost a mean of 2.6 kilograms compared with 0.8 kilograms for placebo, more than triple the placebo effect, alongside modest improvements in cholesterol profile and a reduction in participants with impaired glucose tolerance. Notably, higher doses in this trial did not show a clearly greater effect than the 1 milligram dose, an atypical, non-monotonic dose-response pattern that in retrospect may have been an early signal of the effect’s fragility.
The Pivotal Confirmatory Trial and Its Negative Result
The confirmatory trial that followed, known as the OPTIONS study, was substantially larger and longer: a 24-week, placebo-controlled, adequately powered phase 2b trial enrolling 536 obese adults, purpose-built to confirm the phase 2a signal at a scale sufficient to detect a real effect if one existed. This pivotal trial failed to demonstrate a statistically significant weight-loss benefit of AOD-9604 over placebo across the doses tested. Because this trial was larger, longer, and specifically designed as a confirmatory study, its negative result is the more methodologically reliable finding of the two, and it directly led Metabolic Pharmaceuticals, the compound sponsor, to terminate AOD-9604 clinical development for obesity in 2007.
The Unpublished Pivotal Trial: An Evidence-Quality Concern in Its Own Right
A specific and important limitation of the AOD-9604 evidence base is that the pivotal, 536-participant phase 2b trial result was disclosed only through a company press release and does not appear to have ever been published in a peer-reviewed journal. This is distinct from, and in some ways more concerning than, simply having a small amount of human data: a trial of this size, in an adequately powered confirmatory design, represents a substantial and clinically decisive dataset that has never been made available for independent statistical or methodological scrutiny through standard peer review. Unpublished negative trials are a recognized source of bias in the broader pharmaceutical literature, and in AOD-9604 case, the practical consequence is that the single most important trial in its development history cannot be independently verified beyond the sponsor’s own public statements.
Absence of Subsequent Human Trials
No controlled human trial has re-evaluated AOD-9604 for obesity, weight loss, body composition, or any other outcome since its 2007 development termination. Current marketing claims for joint and cartilage health, common among research-chemical vendors selling AOD-9604 today, have no basis in either the phase 2a or phase 2b trial program, both of which studied obesity and weight loss exclusively, and represent an extrapolation beyond any tested indication.
Safety and Tolerability
The published phase 2a trial reported AOD-9604 as generally well tolerated at the doses tested, though a detailed, independently reviewable adverse-event profile is not extensively available in the public literature. Because the larger phase 2b trial was never published, its safety data are similarly unavailable for independent review beyond whatever was disclosed in the sponsor’s original public statements. Long-term safety beyond the 24-week duration of the longest published trial has not been characterized, and the injectable form now sold by research-chemical vendors was not the route used in either published human trial, meaning even the limited historical safety data may not fully apply to the product currently available.
Regulatory Status
AOD-9604 is not approved by the FDA, the EMA, or any other regulatory authority for any indication. Its clinical development for obesity, sponsored by the Australian company Metabolic Pharmaceuticals, was terminated in 2007 following the negative pivotal phase 2b trial. It is not a dietary supplement and has no legitimate over-the-counter regulatory pathway; it is sold today exclusively through research-chemical vendors and some compounding sources, in both oral and injectable forms, none manufactured under pharmaceutical quality-control standards, and none supported by an approved labeling document. As a fragment derived from human growth hormone, AOD-9604 falls within the growth hormone and growth hormone fragment class prohibited under World Anti-Doping Agency rules, a status relevant to any athlete considering its use despite its lack of any approved medical indication.
Dosing Guidance
No dose of AOD-9604 has been confirmed effective in a published, peer-reviewed human trial. The earlier phase 2a trial tested oral doses from 1 to 30 milligrams daily, with the 1 milligram dose producing the largest reported effect, but the larger, more reliable phase 2b confirmatory trial found no statistically significant benefit over placebo at any dose tested in a comparable range. Both published human trials used oral dosing; current research-chemical vendors predominantly sell an injectable, subcutaneous form, a route not used in either published human trial, meaning vendor dosing recommendations for the injectable product are not derived from the original human trial data and should not be equated with a clinically established regimen.
Clinical and Practical Considerations
AOD-9604 is not approved by the FDA, EMA, or any other regulatory authority for any indication; its clinical development for obesity was terminated by its sponsor in 2007 after the pivotal confirmatory trial failed to show a benefit over placebo
The pivotal negative phase 2b trial (n=536, 24 weeks) was disclosed only through a company press release and does not appear to have been published in a peer-reviewed journal, an important evidence-quality gap distinct from simply having limited data
Marketing for AOD-9604 frequently cites only the earlier, smaller, and less reliable phase 2a trial results (2.6 kilograms weight loss over 12 weeks) while omitting the larger, more rigorous phase 2b trial that found no benefit; readers should weigh the confirmatory negative trial more heavily than the earlier positive signal
No controlled human trial has evaluated AOD-9604 for any outcome since 2007, including the joint and cartilage health claims currently used in some of its marketing
Current research-chemical AOD-9604 is sold predominantly as an injectable product, a route not used in either published human trial, both of which tested an oral formulation
AOD-9604 has not been associated with significant IGF-1 elevation in the available preclinical and limited human data, a mechanistically favorable distinction from full-length growth hormone and growth hormone secretagogues, though this has not been confirmed with dedicated long-term human monitoring
Anyone considering AOD-9604 for weight management should be aware that a properly sized, confirmatory human trial did not find a benefit over placebo, and should be evaluated by a qualified clinician regarding weight-management approaches with a stronger evidence base
As a growth-hormone-derived fragment, AOD-9604 falls within the growth hormone and growth hormone fragment class prohibited by the World Anti-Doping Agency, relevant to athletes
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The foundational paper characterizing the synthetic lipolytic domain of human growth hormone that became AOD-9604, establishing its metabolic activity separate from the growth-promoting domain of the full hormone; preclinical characterization, not a human efficacy trial.
An in vivo rodent study finding that chronic AOD-9604 treatment increased fat oxidation and reduced weight in obese mice comparably to full-length growth hormone but without the associated IGF-1 rise; animal data, not a human trial.
The pivotal mechanistic study demonstrating, using beta-3-adrenergic-receptor knockout mice, that the lipolytic effect of AOD-9604 depends entirely on an intact ADRB3 pathway; in vivo rodent genetic evidence, not human data.
A contemporaneous review of AOD-9604 development status during the mid-2000s, summarizing the early phase 2a human trial results and mechanistic rationale prior to the pivotal phase 2b trial that ultimately found no benefit.
A review of obesity drug candidates in development during the mid-2000s, including AOD-9604, providing independent contemporaneous context on its trial status shortly before the pivotal phase 2b trial results were reported.
A later review of medical obesity treatments that includes AOD-9604 among discontinued or unsuccessful pharmacologic candidates, providing retrospective context on its development outcome.
A recent review of approved and unapproved peptide therapies used in athletic and musculoskeletal contexts, providing current regulatory and safety framing relevant to growth-hormone-fragment peptides such as AOD-9604 marketed for body composition and joint health.
A review of growth hormone and growth hormone fragment doping in competitive sport, providing the regulatory and anti-doping context relevant to AOD-9604 status as a growth-hormone-derived compound under World Anti-Doping Agency rules.